279 related articles for article (PubMed ID: 25804769)
61. Stem cell transplantation in acute myelogenous leukemia in first remission: what are the options?
Mathews V; DiPersio JF
Curr Hematol Rep; 2004 Jul; 3(4):235-41. PubMed ID: 15217552
[TBL] [Abstract][Full Text] [Related]
62. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
[TBL] [Abstract][Full Text] [Related]
63. Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission.
Usuki K; Kurosawa S; Uchida N; Yakushiji K; Waki F; Matsuishi E; Kagawa K; Furukawa T; Maeda Y; Shimoyama M; Ago H; Yamano Y; Yano S; Fujishima N; Takamatsu Y; Eto T; Hidaka M; Matsuoka H; Fukuda T
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):444-51. PubMed ID: 22999942
[TBL] [Abstract][Full Text] [Related]
64. Allogeneic hematopoietic cell transplantation for adult patients with treatment-related acute myeloid leukemia during first remission: Comparable to de novo acute myeloid leukemia.
Tang FF; Huang XJ; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang Y; Wang JZ; Yan CH; Sun YQ; Mo XD; Liu KY; Xu LP
Leuk Res; 2016 Aug; 47():8-15. PubMed ID: 27239735
[TBL] [Abstract][Full Text] [Related]
65. The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.
Rubio MT; Savani BN; Labopin M; Polge E; Niederwieser D; Ganser A; Schwerdtfeger R; Ehninger G; Finke J; Renate A; Craddock C; Kröger N; Hallek M; Jindra P; Mohty M; Nagler A
J Hematol Oncol; 2016 Aug; 9(1):65. PubMed ID: 27488518
[TBL] [Abstract][Full Text] [Related]
66. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
[TBL] [Abstract][Full Text] [Related]
67. Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype.
Sirohi B; Powles R; Singhal S; Smith K; Jones RL; Saso R; Kulkarni S; Treleaven J; Swansbury GJ; Potter M; Morgan G; Mehta J
Leuk Lymphoma; 2008 Dec; 49(12):2284-90. PubMed ID: 19052975
[TBL] [Abstract][Full Text] [Related]
68. Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia.
Karlsson L; Forestier E; Hasle H; Jahnukainen K; Jónsson ÓG; Lausen B; Norén Nyström U; Palle J; Tierens A; Zeller B; Abrahamsson J
Br J Haematol; 2017 Aug; 178(4):592-602. PubMed ID: 28439893
[TBL] [Abstract][Full Text] [Related]
69. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J;
Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677
[TBL] [Abstract][Full Text] [Related]
70. Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.
Hemmati PG; Terwey TH; Na IK; le Coutre P; Jehn CF; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2015 May; 94(5):431-8. PubMed ID: 25220715
[TBL] [Abstract][Full Text] [Related]
71. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
72. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
Kayser S; Hills RK; Langova R; Kramer M; Guijarro F; Sustkova Z; Estey EH; Shaw CM; Ráčil Z; Mayer J; Zak P; Baer MR; Brunner AM; Szotkowski T; Cetkovsky P; Grimwade D; Walter RB; Burnett AK; Ho AD; Ehninger G; Müller-Tidow C; Platzbecker U; Thiede C; Röllig C; Schulz A; Warsow G; Brors B; Esteve J; Russell NH; Schlenk RF; Levis MJ
Br J Haematol; 2021 Mar; 192(5):832-842. PubMed ID: 33529373
[TBL] [Abstract][Full Text] [Related]
73. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
[TBL] [Abstract][Full Text] [Related]
74. [Comparative analysis between autologous and allogeneic hematopoietic stem cell transplantation in 114 adult patients with acute lymphoblastic leukemia in long-term follow-up].
Bao YS; Jiang EL; Wang M; Wang H; Huang Y; Wei JL; Yang DL; Feng SZ; Qiu LG; Han MZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1325-9. PubMed ID: 19099637
[TBL] [Abstract][Full Text] [Related]
75. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S
Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440
[TBL] [Abstract][Full Text] [Related]
76. Comparison of allo-SCT, auto-SCT and chemotherapy for the treatment of patients with low- or intermediate-risk acute myeloid leukemia: a network meta-analysis.
Ye W; Wu X; Zhao R; Jin X; Li H; Qu Y; Ji J; Liu Z
Stem Cell Res Ther; 2024 May; 15(1):153. PubMed ID: 38816870
[TBL] [Abstract][Full Text] [Related]
77. Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia.
Hsieh YY; Hong YC; Hsiao LT; Yu YB; Liu JH; Gau JP; Lin HN; Hsu YN; Chiou TJ; Chen PM; Tzeng CH; Liu CY
Eur J Haematol; 2011 Mar; 86(3):237-45. PubMed ID: 21155895
[TBL] [Abstract][Full Text] [Related]
78. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results.
Ferrara F; Izzo T; Criscuolo C; Riccardi C; Celentano M; Mele G
Am J Hematol; 2010 Sep; 85(9):687-90. PubMed ID: 20652967
[TBL] [Abstract][Full Text] [Related]
79. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
80. Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation.
Beyar-Katz O; Lavi N; Ringelstein-Harlev S; Henig I; Yehudai-Ofir D; Haddad N; Fineman R; Ofran Y; Nov Y; Sahar D; Moustafa-Hawash N; Rowe JM; Zuckerman T
Leuk Lymphoma; 2019 Oct; 60(10):2449-2456. PubMed ID: 30943060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
